Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Elevance Health (ELV)

NYSE: ELV · Healthcare Plans · Indianapolis, IN

Our rating: Cautious

Call changed from Neutral to Cautious at $414.41, moderate conviction, October 28, 2026.

Breaks if: The cautious view is wrong if free cash flow recovers to $4.8B or above on a trailing twelve-month basis while net margin holds at or above 3.5% through two consecutive quarterly filings — conditions that would signal medical cost pressure has peaked and that reported earnings are being backed by real cash generation. On price, a sustained move above $497 (approximately 20% from here) within the next twelve months, absent those fundamental improvements, would also force a re-examination of this call.

Key figures

Market value$85.2B
Revenue, last 12 months$201.8B
Net income, last 12 months$5.1B
Free cash flow, last 12 months$6.5B
Price to earnings16.6×
Free cash flow yield7.6%
Dividend yield1.7%
Operating margin2.7%
Return on equity11.6%
Beta to the S&P 5000.22
Volatility, annualized34.4%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$51.4B1.4%$6.27$1.0B
June 30, 2026$50.5B1.4%$6.71$1.6B
March 31, 2026$50.2B2.6%$8.00$4.1B
December 31, 2025$49.7B9.5%$2.54−$209M
September 30, 2025$50.7B12.4%$5.32$775M
June 30, 2025$49.8B13.4%$7.72$1.8B
March 31, 2025$48.9B14.8%$9.61$821M
December 31, 2024$45.4B6.6%$1.87$384M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

20 ledger entries and 23 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.